As the global leader in diabetes care, GLP-1 peptide therapeutics (Ozempic, Rybelsus), obesity treatments (Wegovy), and rare disease formulations, Novo Nordisk A/S (NYSE: NVO) represents an exemplary biopharmaceutical case study for quantitative AAOIFI Shariah compliance alongside world-class institutional ESG leadership.

Sector Screening

1. Core Business Activity & Permissibility

Novo Nordisk operates across two primary healthcare franchises: Diabetes & Obesity Care and Rare Disease Therapies (hemophilia, growth disorders):

Status: Permissible (Halal)

Therapeutics & Metabolic Health

Discovering, developing, and manufacturing life-saving chronic disease treatments serves human life preservation (Hifz al-Nafs) and is a fully permissible (Halal) core commercial enterprise.

Purification Area

Treasury Yields & Incidental Finance

Incidental income from global cash management, currency hedge gains, and conventional bank interest accounts for < 1.00% of gross revenue, requiring dividend purification.

Quantitative Screen (AAOIFI Standard No. 21)

2. Financial Ratio Compliance Audit

Financial leverage, liquid holdings, and non-permissible revenue ceilings evaluated under AAOIFI Shariah Standard No. 21 parameters:

Screening Metric	AAOIFI Standard Limit	Current Audit Status	Compliance Verdict
Interest-Bearing Debt / Market Cap	< 30.00%	Maintains low leverage; corporate borrowings and lease obligations represent ~4.20% of total market capitalization.	Compliant (Passed)
Interest-Bearing Cash / Market Cap	< 30.00%	Cash reserves, bank deposits, and liquid short-term investments remain safely below the 30% limit (~3.50%).	Compliant (Passed)
Illiquid Assets / Total Assets	≥ 30.00%	Backed by advanced biomanufacturing campuses (Kalundborg expansions), research laboratories, inventory, and patent portfolios.	Compliant (Passed)
Non-Permissible Revenue Ratio	< 5.00%	Incidental treasury interest and non-operating financial income remain well below 5% of total gross revenue (< 0.80%).	Purification Required

ESG Scorecard

3. Environmental, Social, and Governance (ESG) Audit

Novo Nordisk holds a benchmark institutional ESG profile (MSCI ESG Rating: AAA Leader), anchored by its Circular for Zero environmental strategy, Access to Care programs, and foundation ownership:

Environmental (E) AAA • Leader

Circular for Zero & Eco-Pens

Targeting zero environmental impact across operations by 2030; 100% renewable power in production, returpen recycling programs for insulin/GLP-1 injection devices, and green transport logistics.

Social (S) AAA • Leader

Defeat Diabetes & Medicine Access

Access to Care initiatives providing low-cost human insulin to vulnerable populations in least-developed countries; extensive clinical safety oversight and high employee engagement.

Governance (G) AA • Strong

Foundation Ownership & Ethics

Governed by the Novo Nordisk Foundation ensuring long-term mission stability; strict bioethics policies, independent audit oversight, and anti-corruption healthcare compliance.

Executive Summary

4. Screening Verdict & Portfolio Takeaways

✅

Overall Verdict: Shariah-Compliant & Top-Tier ESG Global Leader (MSCI AAA)
Novo Nordisk A/S passes both qualitative core business screening and AAOIFI quantitative financial ratio ceilings with negligible financial leverage. Islamic equity investors receiving dividend distributions must purify the minor non-permissible interest income percentage (< 0.80%) by allocating it to registered charities without expecting religious reward.

Disclaimer: This equity screening case study is prepared strictly for analytical and educational purposes based on AAOIFI Shariah standards, screening data from Zoya and Musaffa, and institutional ESG disclosure frameworks. It does not constitute formal religious rulings (Fatwas) or financial investment advice.